A BILL 
To amend the Bipartisan Congressional Trade Priorities and 
Accountability Act of 2015 to include principal negoti-
ating objectives of the United States relating to trade 
in pharmaceutical products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘International Pharma-
4
ceutical Supply Chain Security Agreement Act of 2021’’. 
5
02:21 Aug 07, 2021
H4711
2 
•HR 4711 IH
SEC. 2. PRINCIPAL NEGOTIATING OBJECTIVES OF THE 
1
UNITED STATES RELATING TO TRADE IN 
2
COVERED PHARMACEUTICAL PRODUCTS. 
3
Section 102(b) of the Bipartisan Congressional Trade 
4
Priorities and Accountability Act of 2015 (19 U.S.C. 
5
4201(b)) is amended by adding at the end the following: 
6
‘‘(23) TRADE
IN
COVERED
PHARMACEUTICAL 
7
PRODUCTS.— 
8
‘‘(A) IN
GENERAL.—With respect to an 
9
agreement relating to trade in covered pharma-
10
ceutical products that is proposed to be entered 
11
into with the United States and to which sec-
12
tion 103(b) will apply, the principal negotiating 
13
objectives of the United States are the fol-
14
lowing: 
15
‘‘(i) To ensure that a party to the 
16
agreement adopts and maintains measures 
17
to eliminate the imposition or reimposition 
18
of tariffs on imports of such products, par-
19
ticularly in the event of a declared emer-
20
gency. 
21
‘‘(ii) To ensure that a party to the 
22
agreement— 
23
‘‘(I) will reduce or eliminate reg-
24
ulatory and other technical barriers in 
25
the pharmaceutical sector; 
26
02:21 Aug 07, 2021
H4711
3 
•HR 4711 IH
‘‘(II) will promote expedited ap-
1
proval of facilities for the production 
2
of such products being built by busi-
3
ness enterprises that operate one or 
4
more such facilities in the territory of 
5
the party; 
6
‘‘(III) will promote the use of 
7
good regulatory practices and stream-
8
lined regulatory review and approval 
9
processes for the production of such 
10
products in the territory of the party; 
11
‘‘(IV) will eliminate duplicated 
12
actions and other barriers to reduce 
13
the time for approvals of both facili-
14
ties and such products; and 
15
‘‘(V) will expand transparency 
16
and cooperation with other parties 
17
and their manufacturers, working col-
18
laboratively, 
to 
ensure 
regulatory 
19
processes are streamlined and har-
20
monized among other parties to the 
21
maximum extent possible. 
22
‘‘(iii) To prohibit export restraints 
23
against parties to the agreement, particu-
24
larly in the event of a declared emergency. 
25
02:21 Aug 07, 2021
H4711
4 
•HR 4711 IH
‘‘(iv) With respect to use of sub-
1
sidies— 
2
‘‘(I) to encourage the coordinated 
3
provision of those types of subsidies 
4
that are classified under World Trade 
5
Organization rules as ‘non-prohibited’, 
6
such as subsidies that are not contin-
7
gent on exports or import-substi-
8
tution, to incentivize manufacturing of 
9
such products, including the provision 
10
of grants, loans, tax incentives, and 
11
guaranteed price and volume con-
12
tracts; 
13
‘‘(II) to explicitly permit, among 
14
parties to the agreement, the use of 
15
production subsidies to build pharma-
16
ceutical manufacturing capacity; 
17
‘‘(III) to affirm that subsidies 
18
provided by parties are not intended 
19
to be used primarily for export or to 
20
distort trade; 
21
‘‘(IV) to affirm parties’ commit-
22
ments under the Antidumping Agree-
23
ment and the Agreement on Subsidies 
24
and Countervailing Measures, includ-
25
02:21 Aug 07, 2021
H4711
5 
•HR 4711 IH
ing the recognition that ‘dumping, by 
1
which products of one country are in-
2
troduced into the commerce of an-
3
other country at less than the normal 
4
value of the products, is to be con-
5
demned if it causes or threatens mate-
6
rial injury to an established industry 
7
in the territory of a contracting party 
8
or materially retards the establish-
9
ment of a domestic industry’; and 
10
‘‘(V) to encourage notification 
11
and consultation among parties as 
12
they are considering pharmaceutical 
13
manufacturing subsidies to increase 
14
coordination and avoid creating condi-
15
tions such as oversupply or market in-
16
efficiencies among the parties. 
17
‘‘(v) With respect to government pro-
18
curement— 
19
‘‘(I) to provide reciprocal access 
20
to government procurements for such 
21
products in parties to the agreement; 
22
‘‘(II) to increase coordination be-
23
tween participant countries and facili-
24
tate the involvement of participant 
25
02:21 Aug 07, 2021
H4711
6 
•HR 4711 IH
countries’ companies in bids to supply 
1
such products; and 
2
‘‘(III) to ensure that any partici-
3
pant in the agreement that is not al-
4
ready so designated, becomes des-
5
ignated for purposes of section 301 of 
6
the Trade Agreements Act of 1979 
7
(19 U.S.C. 2511). 
8
‘‘(vi) With respect to trade in serv-
9
ices— 
10
‘‘(I) to obtain fair, open, and 
11
transparent access to supply chain 
12
services in the markets of parties to 
13
the agreement, such as distribution, 
14
logistics, and transportation services; 
15
‘‘(II) to ensure any restrictions 
16
or regulatory requirements maintained 
17
on such services are adopted and 
18
maintained in a transparent and effi-
19
cient manner; and 
20
‘‘(III) to require parties to estab-
21
lish an internal process for identifying 
22
restrictions or regulatory require-
23
ments that could be waived in the 
24
event of a declared emergency. 
25
02:21 Aug 07, 2021
H4711
7 
•HR 4711 IH
‘‘(vii) With respect to transparency 
1
and trade facilitation— 
2
‘‘(I) 
to 
obtain 
commitments 
3
among parties to the agreement to de-
4
velop mechanisms for sharing infor-
5
mation 
on 
pharmaceutical 
supply 
6
chain constraints and coordinate ap-
7
proaches with parties to minimize 
8
risks that could lead to supply chain 
9
failures; and 
10
‘‘(II) to the extent they have not 
11
done so yet, to obtain commitments 
12
from parties that they will fully imple-
13
ment the obligations under the World 
14
Trade Organization’s Agreement on 
15
Trade Facilitation prior to the date 
16
the agreement enters into force. 
17
‘‘(viii) With respect to enforcement— 
18
‘‘(I) to ensure that benefits under 
19
the agreement can only be obtained by 
20
parties that are fully meeting their ob-
21
ligations under the agreement; 
22
‘‘(II) to ensure that parties will 
23
not bring a dispute under another 
24
02:21 Aug 07, 2021
H4711
8 
•HR 4711 IH
agreement for actions that are con-
1
sistent with the agreement; and 
2
‘‘(III) to provide a dispute settle-
3
ment mechanism comparable to the 
4
dispute settlement provisions of the 
5
Agreement between the United States 
6
of America, the United Mexican 
7
States, and Canada. 
8
‘‘(ix) To minimize the ability of par-
9
ties to the agreement to undermine the ef-
10
fectiveness of the agreement by abusing ex-
11
ceptions in the agreement by including ad-
12
ditional procedural requirements, such as 
13
notification of intent to rely on an excep-
14
tion at the time an inconsistent action is 
15
taken, and limiting the duration that par-
16
ticipants may rely on an exception. 
17
‘‘(B) DEFINITIONS.—In this paragraph: 
18
‘‘(i) ACTIVE PHARMACEUTICAL INGRE-
19
DIENT.—The term ‘active pharmaceutical 
20
ingredient’— 
21
‘‘(I) means any component that 
22
is intended to furnish pharmacological 
23
activity or other direct effect in the 
24
diagnosis, cure, mitigation, treatment, 
25
02:21 Aug 07, 2021
H4711
9 
•HR 4711 IH
or prevention of a disease, or to affect 
1
the structure or any function of the 
2
body of a human or animal; and 
3
‘‘(II) does not include— 
4
‘‘(aa) intermediates used in 
5
the synthesis of a drug product; 
6
or 
7
‘‘(bb) components that may 
8
undergo chemical change in the 
9
manufacture of a drug product 
10
and be present in a drug product 
11
in a modified form that is in-
12
tended to furnish such activity or 
13
effect. 
14
‘‘(ii) AGREEMENT ON SUBSIDIES AND 
15
COUNTERVAILING
MEASURES.—The term 
16
‘Agreement on Subsidies and Counter-
17
vailing Measures’ means the agreement re-
18
ferred to in section 101(d)(12) of the Uru-
19
guay Round Agreements Act (19 U.S.C. 
20
3511(d)(12)). 
21
‘‘(iii) ANTIDUMPING
AGREEMENT.— 
22
The term ‘Antidumping Agreement’ means 
23
the Agreement on Implementation of Arti-
24
cle VI of the General Agreement on Tariffs 
25
02:21 Aug 07, 2021
H4711
10 
•HR 4711 IH
and Trade 1994 referred to in section 
1
101(d)(7) of the Uruguay Round Agree-
2
ments Act (19 U.S.C. 3511(d)(7)). 
3
‘‘(iv) 
BIOLOGICAL
PRODUCT.—The 
4
term ‘biological product’ has the meaning 
5
given to such term in section 351(i) of the 
6
Public Health Service Act (42 U.S.C. 
7
262(i)). 
8
‘‘(v) 
COVERED
PHARMACEUTICAL 
9
PRODUCT.—The term ‘covered pharma-
10
ceutical product’ means— 
11
‘‘(I) a drug (including a biologi-
12
cal product); or 
13
‘‘(II) an active pharmaceutical 
14
ingredient.’’. 
15
SEC. 3. REAUTHORIZATION OF TRADE AGREEMENTS AU-
16
THORITY. 
17
Section 103 of the Bipartisan Congressional Trade 
18
Priorities and Accountability Act of 2015 (19 U.S.C. 
19
4202) is amended— 
20
(1) in subsection (a)— 
21
(A) by striking ‘‘July 1, 2018’’ each place 
22
it appears and inserting ‘‘July 1, 2023’’; and 
23
(B) by striking ‘‘July 1, 2021’’ each place 
24
it appears and inserting ‘‘July 1, 2026’’; 
25
02:21 Aug 07, 2021
H4711
11 
•HR 4711 IH
(2) in subsection (b)— 
1
(A) by striking ‘‘July 1, 2018’’ each place 
2
it appears and inserting ‘‘July 1, 2023’’; and 
3
(B) by striking ‘‘July 1, 2021’’ each place 
4
it appears and inserting ‘‘July 1, 2026’’; and 
5
(3) in subsection (c)— 
6
(A) by striking ‘‘July 1, 2018’’ each place 
7
it appears and inserting ‘‘July 1, 2023’’; 
8
(B) by striking ‘‘June 30, 2018’’ and in-
9
serting ‘‘June 30, 2023’’; 
10
(C) in paragraph (1)(B), by striking ‘‘July 
11
1, 2021’’ and inserting ‘‘July 1, 2026’’; 
12
(D) in paragraph (2), by striking ‘‘April 1, 
13
2018’’ and inserting ‘‘April 1, 2023’’; and 
14
(E) in paragraph (3), by striking ‘‘June 1, 
15
2018’’ and inserting ‘‘June 1, 2023’’. 
16
Æ 
02:21 Aug 07, 2021
H4711
